(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 3 July 2003 (03.07.2003)

(10) International Publication Number WO 2003/053349 A3

(51) International Patent Classification7:

A61K 38/12

(21) International Application Number:

PCT/US2002/039926

(22) International Filing Date:

13 December 2002 (13.12.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/344,080

20 December 2001 (20.12.2001)

60/382,103

20 May 2002 (20.05.2002)

- (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000 (US).
- (72) Inventors: CAMPBELL, Jeffrey, Allen; 525 Alpine Drive, Cheshire, CT 06410 (US). GOOD, Andrew, Charles; 52 High Hill Road, Wallingford, CT 06492 (US).
- (74) Agents: DUBOFF, Samuel et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

(88) Date of publication of the international search report: 15 January 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INHIBITORS OF HEPATITIS C VIRUS

(57) Abstract: The present invention relates to macrocyclic compounds, methods for making these compounds, pharmaceutical compositions and the therapeutic or prophylactic use of these compounds by administering said compounds to mammals to prevent or treat hepatitis C virus (HCV) infection.

SEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/39926

Minimum documentation searched (classification system followed by classification symbols) U.S.: 530/317; 435/5; 435/6. AGIK 38/05, 38/06; AGIP 31/14; COTK 5/08, 5/078 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Please See Continuation Sheet Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Internal Structure Search (CAS-STR Registry, HCAPLUS, CAOLD, USPATFULL, MARPAT, MARPATPREV); Internal Patent Search (CAS-STR Registry, HCAPLUS, CAOLD, USPATFULL, MARPAT, MARPATPREV); Internal Patent Search (CAS-STR Registry, HCAPLUS, CAOLD, USPATFULL, MARPAT, MARPATPREV); Internal Patent Search (PALM). C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Clation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. WO 00/059929 A1 (BOEHRINGER RNGELHEIM (CANADA) LTD., 12 October 2000 (12, 20, 00), claim 1 (compound, is -C- bound to cyclopropyl), claim 54 (method of inhibiting HCV NS3 protease), claim 55 (pharmaceutical composition and carrier), claim 62 (medicament for realment of a mammal with HCV)/Glaso disclosed on specification pages 2, 20, and 22). Y US 6,32,180 B1 (LLINAS-BRUNET et al.) 27 Novermber 2001 (27.11.01), claims (teaches use of sulfonyl compound in treatment of HCV NS3 protease inhibition, along with use of cyclopropyl). ** ** Special estepries of ched documents: *** *** document felining the general state of the art with its not considered to be of particular relevance for children's in investine step when the constituent of the const	A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K 38/12 US CL : 530/317 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED					
Please Sec Continuation Sheet Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Internal Structure Search (CAS-STN Registry, HCAPLUS, CAOLD, USPATFULL, MARPAT, MARPATPREV); Internal Patent Search (EAST-USPAT, US-PGPUB, EPO, JPO, DERWENT); Internal Inventor Search (PALM). C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Y WO 00059929 A1 (BOBERINGER NIGHLEIGM (CANADA) LTD., 12 October 2000 (12.20.00), claim 14 (compound, 1st -C- bound to cyclopropyl), claim 54 (method of inbibiting HCV NS3 protease), claim 55 (pharmacautical composition and carrier), claim 62 (medicament for treatment of a mammal with HCV)[also disclosed on specification pages 2, 20, and 22]. Y US 6,323,180 B1 (LLINAS-BRUNET et al.) 27 Novermber 2001 (27.11.01), claims (teaches use of sulfonyl compound in treatment of HCV NS3 protease inhibition, along with use of cyclopropyl). ** Special categories of chied documents: **A* document defining the general state of the art which is not considered to be of particular relevance the children of the protection of particular relevance to a contract the context which may throw doubts on priority claim(s) or which is claim of the context which may throw doubts on priority claim(s) or which is lade to establish the publication or other special reason (see the context of particular relevance, the childment is claimed invention cannot be considered to be care cannot be considered to involve an invention cannot be considered to	, , , , , , , , , , , , , , , , , , , ,					
Internal Structure Search (CAS-STN Registry, HCAPLUS, CAOLD, USPATFULL, MARPÁT, MARPATPREV); Internal Patent Search (EAST-USPAT, US-PCPUB, EPO, JPO, DERWENT); Internal Inventor Search (PALM). C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Y						
Category* Citation of document, with indication, where appropriate, of the relevant passages Y WO 00/059929 A1 (BOEHRINGER INGELHEIM (CANADA) LTD., 12 October 2000 (12,20,00), claim 1 (compound, 1st -C. bound to eyclopropyl), claim 54 (method of inhibiting HCV NS3 protease), claim 55 (pharmacautical composition and carrier), claim 62 (medicament for treatment of a mammal with HCV)[also disclosed on specification pages 2, 20, and 22]. Y US 6,323,180 B1 (LLINAS-BRUNET et al.) 27 Novermber 2001 (27.11.01), claims (teaches use of sulfonyl compound in treatment of HCV NS3 protease inhibition, along with use of cyclopropyl). **Special categories of cited documents: **A* Special categories of cited documents: **A* Special categories of cited documents: **A* Socument defining the general state of the art which is not considered to be of particular relevance of particular relevance; the claimed invention cannot be considered to involve an investive step when the document which may throw dochts on priority claim(s) or which is clied to establish the publication date of another clustron or other special reason (as specified) **C** document spatished-prior to the international fling date but later than the priority date claimed **C** document spatished-prior to the international fling date but later than the priority date claimed invention cannot be considered to involve an investive step when the document is combined with one or arms other such document is combined with one or arms other such document is combined with one or arms other such document is combined with one or arms other such document is combined with one or arms other such document is combined with one or arms other such document is combined with one or arms other such document is combined with one or arms other such document is combined with one or arms other such document is combined with one or arms other such document is combined with one or arms other such document is combined with one or arms other such document is combined with one or arms oth	Internal Structure Search (CAS-STN Registry, HCAPLUS, CAOLD, USPATFULL, MARPAT, MARPATPREV); Internal Patent					
Y WO 00/05999 A1 (BOEHRINGER INGELHEIM (CANADA) LTD., 12 October 2000 (12.20.00), claim 1 (compound, 1st -C- bound to cyclopropyl), claim 54 (method of inhibiting HCV NS3 protease), claim 55 (pharmacautical composition and carrier), claim 62 (medicament for treatment of a mammal with HCV)(also disclosed on specification pages 2, 20, and 22]. Y US 6,323,180 B1 (LLINAS-BRUNET et al.) 27 November 2001 (27.11.01), claims (teaches use of sulfonyl compound in treatment of HCV NS3 protease inhibition, along with use of cyclopropyl). ** Special categories of clied documents: "A" ** Special categories of clied documents: "A" ** Comment which may throw doubts an priority claim(6) or which is clied to catellath the publication date of another clustice or other special reason (as upselfied) ** comment which may throw doubts an priority claim(6) or which is clied to establish the publication date of another clustice or other special reason (as upselfied) ** document referring to an oral disclosure, use, exhibition or other means priority date claimed ** Date of the actual completion of the international search ** Date of the actual completion of the international search ** The document referring to an oral disclosure, use, exhibition or other means be formly date claimed ** Date of the actual completion of the international search ** The document referring to an oral disclosure, use, exhibition or other means being dividual to an arrange of the search documents, such combination being dividual to a person skilled in the service of the actual completion of the international search ** The document member of the same patent family ** Date of the actual completion of the international search ** The document member of the same patent family ** The document referring to an oral disclosure, use, exhibition or other means being dividual to a person skilled in the service of the same patent family ** The document referring to an oral disclosure, use, exhibition or other means being dividual to a person skilled in t	C. DOC	JMENTS CONSIDERED TO BE RELEVANT				
(12.20.00), claim 1 (compound, 1st -C- bound to cyclopropyl), claim 54 (method of inhibiting HCV NS3 protease), claim 55 (pharmacautical composition and carrier), claim 62 (medicament for treatment of a mammal with HCV)(also disclosed on specification pages 2, 20, and 22]. Y US 6,323,180 B1 (LLINAS-BRUNET et al.) 27 November 2001 (27.11.01), claims (teaches use of sulfonyl compound in treatment of HCV NS3 protease inhibition, along with use of cyclopropyl). * Special categories of cited documents: "A" document defining the general state of the art which is not occaldered to be of particular relevance. The comment which any throw doubts on priority claim(b) or which is cited to establish application date of another claims or other special reason (as specified) "Comment which any throw doubts on priority claim(b) or which is cited to establish application date of another claims or other special reason (as specified) "Comment which any throw doubts on priority claim(b) or which is cited to establish application date of another claims or other special reason (as specified) The comment which any throw doubts on priority claim(b) or which is cited to establish application date of another claims or other means of comment referring to an oral disclosure, use, exhibition or other means of particular relevance, the claimed invention cannot be considered to involve an investive step when the document is tituza alone. "Y" document referring to an oral disclosure, use, exhibition or other means of particular relevance, the claimed invention cannot be considered to involve an investive step when the document is considered to involve an investive step when the document is considered to involve an investive step when the document is considered to involve an investive step when the document is considered to involve an investive step when the document is considered to involve an investive step when the document is considered to involve an investive step when the document is considered to involve an investive step when the				·		
(teaches use of sulfonyl compound in treatment of HCV NS3 protease inhibition, along with use of cyclopropyl). * Purther documents are listed in the continuation of Box C. * Special categories of cited documents: "A" Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance of particular relevance are ariler application or patent published on or after the international filing date or priority decument which may throw doubts on priority claim(s) or which is cited to establish the publication date of another cliation or other special reason (as specifics) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international search "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international search "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international search "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international search "O" April 2003 (07.04.2003) Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Manny Audet Wather Audical Sample and the principle of the same spent family Authorized officer Manny Audet Manny Audet Manny Audet Manny Audet "T" Manne Audical family annex. See patent family annex. See patent family annex. To accument family annex. Box porting date or priority date or priority date or priority date or priority decuments in the suplication with the application to the or priority document for the same spent family and the principle or theory underlying the invention scaled to burders and the principle or theory underl	Y	(12.20.00), claim I (compound, 1st -C- bound to cy inhibiting HCV NS3 protease), claim 55 (pharmacat 62 (medicament for treatment of a mammal with HC	clopropyl), claim 54 (method of utical composition and carrier), claim	1-14		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "B" earlier application or patent published on or after the international filing date of earlier application or patent published on or after the international filing date when the document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search O7 April 2003 (07.04.2003) Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "V" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is taken alone "V" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the accument of particular relevance; the claimed invention cannot be consi	Y	(teaches use of sulfonyl compound in treatment of HCV NS3 protease inhibition, along		1,2,3,9,11		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "B" earlier application or patent published on or after the international filing date of earlier application or patent published on or after the international filing date when the document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search O7 April 2003 (07.04.2003) Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "V" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is taken alone "V" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the accument of particular relevance; the claimed invention cannot be consi						
date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document referring to an oral disclosure, use, exhibition or other means document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search Of April 2003 (07.04.2003) Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 document defining the general state of the art which is not considered to be of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document referring to an oral disclosure, use, exhibition or other means "E" document referring to an oral disclosure, use, exhibition or other means "E" document referring to an oral disclosure, use, exhibition or other means "E" document referring to an oral disclosure, use, e	Further	documents are listed in the continuation of Box C.	See patent family annex.			
"E" cariler application or patent published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search O7 April 2003 (07.04.2003) Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be inventive an inventive step when the document is taken alone "V" document of particular relevance; the claimed invention cannot be considered novel or cannot be inventive an inventive step when the document is taken alone "V" document referring to an oral disclosure, use, exhibition or other means "E" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document referring to an oral disclosure, use, exhibition or other means "E" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined invention to combine the following particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is taken alone "O" do	"A" document defining the general state of the art which is not considered to be		date and not in conflict with the applic	cation but cited to understand the		
establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search O7 April 2003 (07.04.2003) Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 "Y" document published prior to the claimed invention camnot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family The priority date claimed Date of the actual completion of the international search O7 April 2003 (07.04.2003) Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	*B" carlier ap	plication or patent published on or after the international filing date	considered novel or cannot be conside			
"P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search O7 April 2003 (07.04.2003) Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 "&" document member of the same patent family Date of mailing of the international search report 14 AUG 2003 Authorized officer Maury Audet Maury Audet	establish specified	the publication date of another citation or other special reason (as	considered to involve an inventive ste combined with one or more other such	p when the document is a documents, such combination		
Date of the actual completion of the international search O7 April 2003 (07.04.2003) Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Date of mailing of the international search report 14 AUG 2003 Authorized officer Manry Audet Manry Audet	"O" document	referring to an oral disclosure, use, exhibition or other means	being obvious to a person skilled in th	e art		
07 April 2003 (07.04.2003) Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 14 AUG 2003 Authorized officer Manry Audet Manry Audet	priority date claimed					
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Authorized officer Maury Audet Maury Audet	Date of the actual completion of the international search		Date of mailing of the international sea	ren report		
Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Maury Audet Maury Audet			- = AUG 2003	A		
	Commissioner of Patents and Trademarks Box PCT		() and to topal			
10-1			Telephone No. 703-308-0196	701		

Ĭ,		PCT/US02/39926
INTERNATIONAL SEARCH RE	PORT	
	•	
•		
	•	
		·
		·
•		•
Continuation of B. FIELDS SEARCHED Item 2:		•
Structure search: macrocyclic peptide of formula I and I	I, R2, R3, R4, and Q.	R1 (i.e. cyclopropyl), attached to -SOO, was not
searched as -SOO functional group [attached to core pepti	ide (-cyclopropyl-CO-N	H-)] was not found among structures searched.
Term search: macrocyclic, peptide, cyclopropyl, carrier, inhibitor, treatment.	pharmaceutical, compo	osition, "HCV NS3 protease", HCV, NS3 protease,
minorior, deadment.	•	
·		
		•
•		
	•	
•		
	•	
!		

11

Form PCT/ISA/210 (second sheet) (July 1998)